导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.10% | 957/4773 |
| 近一周 | -1.40% | 2127/5465 |
| 近一月 | -4.44% | 3242/5421 |
| 近一季 | -12.86% | 4072/5231 |
| 近半年 | 0.94% | 1235/4920 |
| 近一年 | 12.42% | 952/4394 |
| 近两年 | 90.59% | 715/2954 |
| 近三年 | 42.32% | 711/2253 |
| 成立以来 | 41.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.99% 2052/4961 |
26.42% 1028/5312 |
- - |
- - |
| 2025 | 28.79% 1450/4813 |
5.94% 704/3635 |
2.52% 1519/4076 |
14.30% 2927/4524 |
3.74% 633/4813 |
| 2024 | 0.34% 2080/3463 |
-12.29% 2455/2808 |
-8.18% 2177/3014 |
21.88% 537/3129 |
2.22% 973/3463 |
| 2023 | 3.37% 284/2656 |
16.76% 191/2280 |
-0.73% 410/2385 |
-10.86% 2030/2515 |
0.06% 169/2655 |
| 2022 | -25.95% 1361/2207 |
-18.47% 1342/1919 |
0.94% 1514/2016 |
-14.48% 1102/2113 |
5.21% 479/2208 |
| 2021 | 26.51% 96/1822 |
-11.27% 1131/1255 |
23.46% 116/1330 |
2.99% 422/1466 |
12.13% 83/1822 |
| 2020 | - - |
- - |
4.00% 919/1067 |
5.61% 903/1164 |
-3.69% 1133/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国寿创精选88ETF联接C VS. 长安沪深300非周期A(740101) |